Roche pushes antigen tests for second Covid-19 wave
Diagnostics boom helps the Swiss drug company stick to its 2020 targets
15 October 2020 - 22:03
Zurich — Surging demand globally for Covid-19 tests boosted third-quarter revenues at Swiss drug company Roche's diagnostics business, helping to offset declining drug sales and keeping the group on track to meet 2020 targets.
Roche diagnostics head Thomas Schinecker said rising coronavirus infections in many countries were driving a shift in demand towards cheaper antigen tests since so-called PCR tests, the pandemic mainstay, remain in short supply...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.